The BioREACH program provides milestone-driven translational research funding of up to $50,000 to Stony Brook University faculty and postdoctoral researchers. It aims to bridge the gap between academic discovery and commercial application by supporting projects that resolve key technical or scientific uncertainties, helping to advance biomedical innovations, platforms, and tools toward their next stage of development.
The BioREACH program is a translational research funding initiative designed to bridge the gap between academic discovery and real-world commercial application. It provides up to $50,000 in funding over a 12-month period to Stony Brook University faculty and postdoctoral researchers. The program is specifically intended to support milestone-driven studies that resolve key scientific or technical uncertainties, helping to advance biomedical innovations toward a defined enablement platform, tool, or product.
Key features of the program include:
BioREACH does not fund basic science research. Instead, it focuses on projects that can materially move a technology's readiness level toward commercial viability. Applicants are encouraged to engage with the Center for Biotechnology for an initial assessment of their project's stage and fit before applying.
Stony Brook University is a comprehensive public research university on Long Island and New York’s flagship, recognized as a Carnegie R1 institution and a member of the Association of American Universities. Companies connect through a research and development park with co-located incubators and growth programs, alongside convenient access to New York City and Long Island industry. Health system integration through Stony Brook Medicine enables clinical collaboration and translation, while a co-management role at nearby Brookhaven National Laboratory opens pathways to DOE user facilities and joint initiatives. Research is supported by competitive federal funding from agencies such as NIH, NSF, and DOE. A dedicated technology transfer office, Intellectual Property Partners, streamlines IP, licensing, and industry agreements, including flexible CLEAR‑IP options.